Drug · Adc
Polatuzumab Vedotin
CI-DRUG-00000740Explore in graph →CHEMBL3301582 Approved
Regulatory
Approvals (6)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as POLIVY (DIN 02515431) under ATC L01FX14 POLATUZUMAB VEDOTIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Oct 26, 2021 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as POLIVY (DIN 02499614) under ATC L01FX14 POLATUZUMAB VEDOTIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Nov 25, 2020 | health-canada-dpd |
| EU EMA | Diffuse Large B-Cell Lymphoma | Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 14 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 3 | 45 | 15 | 6 | 68 | 6 | CA, EU, US | Jun 10, 2019 | Mar 22, 2011 |
| Non-Hodgkin Lymphoma | Approved | Phase 3 | 28 | 9 | 5 | 45 | 3 | EU, US | Jun 10, 2019 | Mar 22, 2011 |
| Hodgkin Lymphoma | Phase2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Aug 1, 2021 |
| Leukemia | Phase2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (70)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | active not recruiting | Phase 2 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06890884 | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) |